SCHEMBL783942

SCHEMBL783942

COc1ccc2c(c1F)COc1c-2ccc(OC)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
PGR P06401 2/20 0.34
HSD17B10 Q99714 2/20 0.33
MAPT P10636 2/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
DPP4 P27487 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
LMNA P02545 3/20 0.31
MAPK14 Q16539 1/20 0.31
CYP3A4 P08684 3/20 0.31
TP53 P04637 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12990387 0.91 ESR1 (0.39) ESR1ESR2KDM4EALDH1A1HPGD
SCHEMBL12990799 0.91 ESR1 (0.39) ESR1ESR2KDM4EALDH1A1HPGD
SCHEMBL13039553 0.84 MRGPRX4 (0.44) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL13039557 0.83 APP (0.37) KDM4EMAPTMAPK1ADRA1AACHE
SCHEMBL29331878 0.82 PDE4D (0.33) ESR1ESR2
SCHEMBL13039556 0.81 SGPL1 (0.33) AAK1
SCHEMBL783650 0.77 ESR1 (0.35) ESR1ESR2KDM4EAAK1
SCHEMBL25693989 0.77 S1PR5 (0.35) ESR1ESR2KDM4EALDH1A1HPGD
SCHEMBL25695257 0.76 L3MBTL1 (0.35) ESR1ESR2AAK1
SCHEMBL25574725 0.76 L3MBTL1 (0.35) ESR1ESR2AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400561-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-07-17 EP disclosed
US-11873438-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-01-16 US disclosed
US-11655417-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2023-05-23 US disclosed
US-20170044437-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-02-16 US disclosed
US-20150299574-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2015-10-22 US disclosed
US-9096795-B2 Liquid crystal display MERCK PATENT GMBH (DE) 2015-08-04 US disclosed
US-9096795-B2 Liquid crystal display MERCK PATENT GMBH (DE) 2015-08-04 US disclosed
US-9096795-B2 Liquid crystal display MERCK PATENT GMBH (DE) 2015-08-04 US disclosed
EP-2432851-B1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2013-10-02 EP disclosed
EP-2432851-B1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2013-10-02 EP disclosed
US-20120069289-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-22 US disclosed
US-20120069289-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-22 US disclosed
US-20100309423-A1 Liquid Crystal Display MERCK PATENT GESELLSCHAFT (DE) 2010-12-09 US disclosed
WO-2010133278-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2010-11-25 WO disclosed
WO-2010133278-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2010-11-25 WO disclosed
US-7824745-B2 Benzochromene derivatives MERCK PATENT GMBH (DE) 2010-11-02 US disclosed
US-7678929-B2 Furochroman derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-03-16 US disclosed
US-20090023802-A1 Benzochromene Derivatives MERCK PATENT GMBH (DE) 2009-01-22 US disclosed
US-20080177095-A1 FUROCHROMAN DERIVATIVES MERCK PATENT GMBH (DE) 2008-07-24 US disclosed
US-7326447-B2 Benzochromene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080177095-A1 FUROCHROMAN DERIVATIVES CFD, LMAN1, UROD ESR1 2619/4885ESR2 1410/4885KDM4E 4424/4885
US-20170044437-A1 LIQUID-CRYSTALLINE MEDIUM VIM, COL2A1, COL1A1 ESR1 2530/4885ESR2 2912/4885KDM4E 3492/4885
US-20090023802-A1 Benzochromene Derivatives SBDS, CRY1, DDT ESR1 302/4885ESR2 742/4885KDM4E 3570/4885
US-20120069289-A1 LIQUID CRYSTAL DISPLAY LPXN, VCL, ACP3 ESR1 1013/4885ESR2 2665/4885KDM4E 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.